2949-9690

JAPhA Practice Innovations

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 101 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact101 DOIs
2

Deposit reference lists for 6 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact6 DOIs
3

Attach ORCID iDs across 5 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 101 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 A new framework for elevating and updating clinical language… (10.1016/j.japhpi.2023.100001)
Abstract
23.86 8
2 Medication discrepancies across care transitions and the rol… (10.1016/j.japhpi.2024.100009)
Abstract
17.47 4
3 Diabetes technology: Continuous glucose monitoring and the r… (10.1016/j.japhpi.2023.100005)
Abstract
15.05 3
4 Utilizing pharmacists for billable services related to disea… (10.1016/j.japhpi.2023.100006)
Abstract
15.05 3
5 Scaling the optimizing care model in community pharmacy usin… (10.1016/j.japhpi.2023.100002)
Abstract
11.93 2
6 Impact of pharmacist-led vaccine assessment and patient coun… (10.1016/j.japhpi.2023.100004)
Abstract
11.93 2
7 Permissionless innovation in the pharmacy business model: Th… (10.1016/j.japhpi.2023.100007)
Abstract
11.93 2
8 Opportunities for interprofessional collaboration between ph… (10.1016/j.japhpi.2024.100012)
Abstract
11.93 2
9 Improvement in HIV screening follow-up rates with emergency… (10.1016/j.japhpi.2024.100025)
Abstract
11.93 2
10 Continuous glucose monitoring based glycemic control among u… (10.1016/j.japhpi.2025.100045)
Abstract
11.93 2
11 Pharmacists’ perspectives on psilocybin in Canada (10.1016/j.japhpi.2023.100003)
Abstract
7.53 1
12 Implementation of pharmacist-prescribed contraceptive servic… (10.1016/j.japhpi.2024.100011)
Abstract
7.53 1
13 Impact of pharmacist-led transitions of care model on length… (10.1016/j.japhpi.2024.100015)
Abstract
7.53 1
14 Pharmacist intervention to improve controlled substance disp… (10.1016/j.japhpi.2024.100019)
Abstract
7.53 1
15 Implementation of a collaborative practice agreement for dep… (10.1016/j.japhpi.2024.100021)
Abstract
7.53 1
16 Stronger together: A community case study highlighting the b… (10.1016/j.japhpi.2024.100024)
Abstract
7.53 1
17 Impact of a pharmacist-led smoking cessation service on chan… (10.1016/j.japhpi.2025.100028)
Abstract
7.53 1
18 Enhancing evidence-based decision making through primary car… (10.1016/j.japhpi.2025.100031)
Abstract
7.53 1
19 Implementation of pharmacist-initiated proton pump inhibitor… (10.1016/j.japhpi.2025.100037)
Abstract
7.53 1
20 Impact of pharmacist-led continuous glucose monitoring progr… (10.1016/j.japhpi.2025.100039)
Abstract
7.53 1
21 Impact of a Drug Take Back Day event at a large chain commun… (10.1016/j.japhpi.2025.100042)
Abstract
7.53 1
22 Identifying barriers and facilitators to pharmacist-dietitia… (10.1016/j.japhpi.2025.100052)
Abstract
7.53 1
23 Early implementation of Pharmacist eCare Plan and electronic… (10.1016/j.japhpi.2025.100073)
Abstract
7.53 1
24 Creation of the Ew Meds List-a comprehensive list of bad-tas… (10.1016/j.japhpi.2025.100076)
Abstract
7.53 1
25 Clinical impact of GLP-1 and GIP/GLP-1 agonist access barrie… (10.1016/j.japhpi.2025.100081)
Abstract
7.53 1
26 Evaluation of pharmacist involvement in multidisciplinary ho… (10.1016/j.japhpi.2024.100008)
Abstract
0.00 0
27 Impact of a pharmacist-driven insulin dispensing program in… (10.1016/j.japhpi.2024.100010)
Abstract
0.00 0
28 Evaluation of missed opportunity for clinical pharmacist pra… (10.1016/j.japhpi.2024.100013)
Abstract
0.00 0
29 Measuring pharmacy clinical workload in the emergency depart… (10.1016/j.japhpi.2024.100014)
Abstract
0.00 0
30 Implementing a meningococcal B vaccination multimedia educat… (10.1016/j.japhpi.2024.100016)
Abstract
0.00 0
31 Before you click submit: Double check your manuscript (10.1016/j.japhpi.2024.100022)
Abstract
0.00 0
32 Development of a curriculum to improve PrEP awareness and co… (10.1016/j.japhpi.2024.100023)
Abstract
0.00 0
33 Pharmacists prescribing COVID-19 therapeutics (nirmatrelvir/… (10.1016/j.japhpi.2025.100026)
Abstract
0.00 0
34 Developing ambulatory care clinical pharmacy services in an… (10.1016/j.japhpi.2025.100027)
Abstract
0.00 0
35 A comparison of diltiazem versus metoprolol for patients wit… (10.1016/j.japhpi.2025.100029)
Abstract
0.00 0
36 Impact of a pharmacist-led asthma clinic in a high-risk pedi… (10.1016/j.japhpi.2025.100030)
Abstract
0.00 0
37 Access and acceptance of pharmacist recommendations through… (10.1016/j.japhpi.2025.100032)
Abstract
0.00 0
38 Pharmacist confidence, comfort, and experience screening for… (10.1016/j.japhpi.2025.100033)
Abstract
0.00 0
39 Retrospective analysis of direct oral anticoagulation hold r… (10.1016/j.japhpi.2025.100034)
Abstract
0.00 0
40 Identifying secondary stroke prevention treatment gaps in ol… (10.1016/j.japhpi.2025.100035)
Abstract
0.00 0
41 Determining patient motivators to receiving the respiratory… (10.1016/j.japhpi.2025.100036)
Abstract
0.00 0
42 Development of a framework for implementation of pharmacist-… (10.1016/j.japhpi.2025.100038)
Abstract
0.00 0
43 Impact of a pharmacist-led stewardship intervention for anti… (10.1016/j.japhpi.2025.100040)
Abstract
0.00 0
44 Impact of a community pharmacist referral on the completion… (10.1016/j.japhpi.2025.100041)
Abstract
0.00 0
45 Evaluation of antifungal prophylaxis in pediatric patients w… (10.1016/j.japhpi.2025.100043)
Abstract
0.00 0
46 Exploratory analysis of pharmacist involvement in motivation… (10.1016/j.japhpi.2025.100044)
Abstract
0.00 0
47 Efficacy of GLP-1 agonists vs. other weight management medic… (10.1016/j.japhpi.2025.100046)
Abstract
0.00 0
48 The evaluation of treatment of chlamydia and gonorrhea in th… (10.1016/j.japhpi.2025.100047)
Abstract
0.00 0
49 State of work-life balance and career aspirations among Japa… (10.1016/j.japhpi.2025.100048)
Abstract
0.00 0
50 Assessing Pennsylvania advanced pharmacy practice experience… (10.1016/j.japhpi.2025.100049)
Abstract
0.00 0